The Role Of Vegf, Pdgf And Il-6 On Diabetic Foot Ulcer After Platelet Rich Fibrin Þ Hyaluronic Therapy

Background: Current standard management of diabetic foot ulcers (DFUs) consists of surgical debridement followed by soak NaCl 0.9% gauzes tight infection and glycaemic control. Nowadays the use of advanced plateletrich fibrin (A-PRF) has emerged as an adjunctive method for treating DFUs. This study was conducted to demonstrate the ability of combine A-PRF þ HA as a complementary therapy in DFUs healing related with angiogenesis,inflammation and granulation index process. Methods: This open label randomized controlled trial was conducted in Koja District Hospital and Gatot Soebroto Hospital Jakarta, Indonesia on July 2019–April 2020. DFUs patients with wound duration of three months, Wagner-2, with size of ulcer less than 40 cm2 were included in the study. The number of subjects was calculated based on the rule of thumb and allocated randomly into three groups, namely topical A-PRF þ HA, A-PRF an Sodium Chloride 0.9% as a control, for each of 10 subjects. A-PRF made by 10 mL venous blood, centrifuge 200 G in 10 min, meanwhile A-PRF þ HA though mix both them with vertex machine around 5 min. Biomarker such as VEGF, PDGF and IL-6 examined from DFU taken by cotton swab and analysis using ELISA. Granulation Index was measured using ImageJ. Biomarkers and granulation index were evaluated on day 0, 3, 7 and 14. Data were analysed using SPSS version 20 with Anova and Kruskal Wallis test to compare the angiogenesis and inflammation effect between the three groups. Result: In topical dressing A-PRF þ HA, there is an increase in delta VEGF on day-3 (43.1 pg/mg protein) and day-7 (275,8 pg/mg protein) compared to A-PRF on day-3 (1.8 pg/mg protein) and day-7 (104.7 pg/mg protein), also NaCl (control) on day-3 (-4.9 pg/mg protein) and day-7 (28.3 pg/mg protein). So that the delta VEGF of A-PRF þ HA group increase significantly compared with others on day-3 (p ¼ 0.003) and day-7 (p < 0.001). Meanwhile APRF þ AH group, there is also a decrease in delta IL-6 after therapy on day-3 (-10.9 pg/mg protein) and day-7 (-18.3 pg/mg protein) compared to A-PRF in delta IL-6 on day-3 (-3.7 pg/mg protein) and on day-7 (-7.8 pg/ mg protein). In NaCl (control) group there is a increase delta IL-6 on day-3 (4.3 pg/mg protein) and on day-7 (35.5 pg/mg protein). So that the delta IL-6 of A-PRF þ HA group decrease significantly compared with others only on day-7 (p ¼ 0.015). In PDGF le level analysis, A-PRF þ HA group increase significantly (p ¼ 0.012) only in day -7 compare with other group (5.5 pg/mg protein). Conclusion: The study shows the superior role of combined A-PRF þ HA in the treatment DFU though increase angiogenesis and decrease inflammation pathway. The advantage of using A-PRF þ HA is that it accelerates wound healing by increasing granulation tissue compared to A-PRF alone